Cisplatin-Associated Anaemia Treated with Erythropoietin
Author Information
Author(s): S. Cascinu, A. Fedeli, S. Luzi Fedeli, G. Catalano
Primary Institution: Servizio di Oncologia, Ospedali Riuniti, Pesaro, Italy
Hypothesis
Can subcutaneous erythropoietin effectively treat cisplatin-associated anaemia in cancer patients?
Conclusion
Subcutaneous low doses of erythropoietin are effective and safe for treating cisplatin-induced anaemia.
Supporting Evidence
- Fifteen out of twenty patients showed an increase in haemoglobin levels above 100 g/l.
- Only three patients required blood transfusions, indicating a positive response to treatment.
- The treatment was well tolerated with mild side effects reported.
Takeaway
This study shows that a medicine called erythropoietin can help people with cancer who become anemic from their treatment, making them feel better.
Methodology
Twenty cancer patients with cisplatin-associated anaemia received subcutaneous erythropoietin three times a week, with dose adjustments based on response.
Limitations
The study was a pilot with a small sample size and lacked a control group.
Participant Demographics
11 men and 9 women, median age 52 years (range 45-71).
Want to read the original?
Access the complete publication on the publisher's website